点击“蓝字”关注我们肥胖、射血分数保留的心力衰竭（HFpEF）和慢性肾脏病（CKD）相互作用，肥胖可导致HFpEF和CKD，CKD也会影响肥胖相关HFpEF的病程。促胰素类药物或可影响肾功能，从而影响HFpEF合并肥胖患者的预后。替尔泊肽（tirze ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Based on the Phase II data, Imbria Pharmaceuticals’ inerafaxstat could complement existing treatments rather than replace ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

Compared with those who spent most of their time in a single room, people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

The results were presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) in Chicago ... myocardial energetics in HFpEF and demonstrate ninerafaxstat ...